Continuation Study for Latozinemab

Overview

About this study

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
* Has successfully completed participation in their parent latozinemab study.
* Female participants must be nonpregnant and nonlactating.
* Male participants must agree to acceptable contraception use.

Exclusion Criteria:

* Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
* Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/13/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Boeve, M.D.

Contact us for the latest status

Contact information:

Jessica Bauman

(507) 266-9618

Bauman.Jessica@mayo.edu

More information

Publications

Publications are currently not available